These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 21871882)
1. Cloning and pharmacological characterization of the dog cannabinoid CB₂receptor. Ndong C; O'Donnell D; Ahmad S; Groblewski T Eur J Pharmacol; 2011 Nov; 669(1-3):24-31. PubMed ID: 21871882 [TBL] [Abstract][Full Text] [Related]
2. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048 [TBL] [Abstract][Full Text] [Related]
3. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Mukherjee S; Adams M; Whiteaker K; Daza A; Kage K; Cassar S; Meyer M; Yao BB Eur J Pharmacol; 2004 Nov; 505(1-3):1-9. PubMed ID: 15556131 [TBL] [Abstract][Full Text] [Related]
5. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Bolognini D; Cascio MG; Parolaro D; Pertwee RG Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724 [TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Steffens M; Engler C; Zentner J; Feuerstein TJ Br J Pharmacol; 2004 Apr; 141(7):1193-203. PubMed ID: 14993102 [TBL] [Abstract][Full Text] [Related]
7. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Lambert DM; DiPaolo FG; Sonveaux P; Kanyonyo M; Govaerts SJ; Hermans E; Bueb J; Delzenne NM; Tschirhart EJ Biochim Biophys Acta; 1999 Sep; 1440(2-3):266-74. PubMed ID: 10521710 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. Lay L; Angus JA; Wright CE Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Zaniewska M; McCreary AC; Przegaliński E; Filip M Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696 [TBL] [Abstract][Full Text] [Related]
10. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Zhang Y; Xie Z; Wang L; Schreiter B; Lazo JS; Gertsch J; Xie XQ Int Immunopharmacol; 2011 Sep; 11(9):1303-10. PubMed ID: 21539938 [TBL] [Abstract][Full Text] [Related]
11. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. Bonhaus DW; Chang LK; Kwan J; Martin GR J Pharmacol Exp Ther; 1998 Dec; 287(3):884-8. PubMed ID: 9864268 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101 [TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. McMahon LR J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255 [TBL] [Abstract][Full Text] [Related]
15. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists. Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877 [TBL] [Abstract][Full Text] [Related]
16. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363 [TBL] [Abstract][Full Text] [Related]
17. Cannabinoids inhibit noradrenergic and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial bed. Pakdeechote P; Dunn WR; Ralevic V Br J Pharmacol; 2007 Nov; 152(5):725-33. PubMed ID: 17641668 [TBL] [Abstract][Full Text] [Related]